SITE010-0296

SITE010 (ESP) › SITE010-0296

SITE010-0296

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2026-08-28

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-14 (study day 14); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.